All In Biotech

Drug Trial Radar · NCT07602530

A Study in Canada to Follow Outcomes of Women in Menopause Treated With Fezolinetant for Hot Flashes, When Given in Clinical Practice

A Real-world Observational Study of Outcomes Among Canadian Women With Bothersome VMS Associated With Menopause Who Are Treated With Fezolinetant in a Real-life Setting According to Routine Healthcare Practice

Last checked: Nov 20, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

238

Planned (sponsor's estimate)

Start

Oct 23, 2025

Primary completion

Feb 28, 2027

Study completion Nov 30, 2027

Sponsor

Lead sponsor
Astellas Pharma Europe Ltd.Astellas (ALPMY)
Sponsor type
Industry
First posted
May 22, 2026

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
Female only
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is for women in Canada who are in menopause. They have symptoms including hot flashes and night sweats (also known as vasomotor symptoms or VMS). Their own doctor has prescribed fezolinetant for hot flashes and night sweats, as part of routine health care in Canada. In this study, women will be taking tablets of fezolinetant. This study is about recording information only. The women's own doctor decides on treatment, not the study sponsor (Astellas). Women are taking fezolinetant every day for up to 52 weeks (1 year). The main aim is to learn if fezolinetant improves hot flashes and night sweats after 12 weeks. Other aims are to learn if fezolinetant improves hot flashes and night sweats throughout the study. This includes improved sleep and the women's wellbeing. Details are recorded on how satisfied the women are with fezolinetant and if they completed their treatment. This includes reasons for stopping treatment. Any safety issues are recorded. Details about other treatments taken before or with fezolinetant are also recorded.

Conditions

  • Hot Flashes

Interventions

  • FezolinetantDrug

    Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants reporting improvement in hot flashes/night sweats: Patient Global Impression of Change (PGI-C) VMSTime frame: Week 12

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Site CA15002

    Montreal, Canada · Recruiting

  • Site CA15001

    Prince Albert, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.